BCG

DeepMirror Launches Early Access Programme for Its Intuitive Molecular Drug Design Software

Retrieved on: 
Monday, December 11, 2023

DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.

Key Points: 
  • DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, today announced the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months.
  • The software allows users to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
  • AI-enabled drug discovery programmes often start with pharmaceutical companies partnering with AI companies to deliver insights for their drug discovery efforts.
  • After 12 months of development and a successful beta testing programme, we are excited to officially launch DeepMirror to early adopters.

ZoomInfo Ranked No. 8 on 2023 Fortune Future 50

Retrieved on: 
Wednesday, December 6, 2023

8 on the Fortune Future 50 for 2023, an exclusive list that recognizes the long-term revenue growth prospects of more than 1,700 of the world’s largest public companies.

Key Points: 
  • 8 on the Fortune Future 50 for 2023, an exclusive list that recognizes the long-term revenue growth prospects of more than 1,700 of the world’s largest public companies.
  • Since 2017, Fortune has teamed up with Boston Consulting Group (BCG) to produce the Future 50, an index of companies that are built to deliver robust growth — along with outsized returns for shareholders in the long term.
  • To identify the Future 50, the BCG Henderson Institute examined more than 1,700 publicly traded companies and used a “vitality” index to determine the rankings.
  • “As this ranking demonstrates, ZoomInfo is built for long-term growth,” ZoomInfo Founder and CEO Henry Schuck said.

Sentar Named #1 Best Companies to Work for in Alabama

Retrieved on: 
Tuesday, December 5, 2023

Sentar, Inc. (Sentar), a women-owned small business specializing in advanced cyber intelligence solutions and technology, is excited to announce that they have been awarded first place in the 2023 Best Companies to Work for Alabama in the Large Company category.

Key Points: 
  • Sentar, Inc. (Sentar), a women-owned small business specializing in advanced cyber intelligence solutions and technology, is excited to announce that they have been awarded first place in the 2023 Best Companies to Work for Alabama in the Large Company category.
  • In partnership with Best Companies Group (BCG) and Business Alabama, this survey-and-awards program was designed to identify, recognize, and honor the best companies to work for in the state of Alabama through a research-based evaluation focused on how organizations work, the programs they offer, the benefits they provide, and most importantly, that they gather feedback from employees.
  • “Every Sentar team member has contributed to our collective efforts in achieving this significant milestone of being awarded the Best Company to Work for in Alabama,” said Bridget McCaleb, Catalyst & CEO of Sentar.
  • “As we approach the 34th anniversary of Sentar’s founding, we’d also like to acknowledge the impact of our Huntsville partners and customers who better enable our success.”
    Sentar was recognized along with the state’s other winning employers at the Best Companies to Work for in Alabama ceremony on December 4, 2023 in Birmingham, Alabama.

Introducing Avail: A New Platform Harnessing AI to Help Hollywood Cover More IP and Innovate the Pre-Production Process

Retrieved on: 
Monday, December 4, 2023

Avail’s coverage offering summarizes scripts and books of any length, outputting a hallucination-free detailed summary, character breakdown, and tonal assessment within minutes.

Key Points: 
  • Avail’s coverage offering summarizes scripts and books of any length, outputting a hallucination-free detailed summary, character breakdown, and tonal assessment within minutes.
  • “After months of R&D, we’re thrilled to share Avail with the industry,” said Chris Giliberti, Co-Founder and CEO of Avail.
  • “In my executive days, the biggest challenge I faced was keeping up with the myriad of submissions.
  • Liu built his own platform for students as an undergrad, and began his tech leadership career at startups Chegg and Smule.

CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Tuesday, December 5, 2023

CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.

Key Points: 
  • CG Oncology, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted both Fast Track Designation and Breakthrough Therapy Designation for cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ with or without Ta or T1 (papillary) tumors.
  • “Receiving both FDA Fast Track and Breakthrough Therapy Designation is an important milestone in the development of cretostimogene grenadenorepvec and for patients with bladder cancer who urgently need more therapeutic options,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology.
  • CG Oncology looks forward to working with the FDA to advance cretostimogene grenadenorepvec as a potential backbone therapy in bladder cancer.
  • “The Bladder Cancer Advocacy Network (BCAN) is grateful for the expedited review of this potential treatment option for bladder cancer patients with high-risk BCG-unresponsive NMIBC.

Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Retrieved on: 
Thursday, November 30, 2023

The fully-enrolled trial of 116 patients with BCG-unresponsive NMIBC is taking place across North America and the Asia-Pacific region.

Key Points: 
  • The fully-enrolled trial of 116 patients with BCG-unresponsive NMIBC is taking place across North America and the Asia-Pacific region.
  • The primary endpoint of the study is CR at any time, with duration of response measured as a secondary endpoint.
  • No grade 3 or higher AEs related to cretostimogene grenadenorepvec were observed and there were no treatment discontinuations due to AEs.
  • “Our goal is to transform the treatment landscape for patients with bladder cancer, and these results reinforce our commitment to developing bladder-sparing therapeutics to improve patient outcomes and quality of life.”

Tyfone Appoints Tom Shen, Santo Cannone, Laurent Desmangles to Board of Directors

Retrieved on: 
Wednesday, November 29, 2023

Tyfone , the preeminent force in digital transformation, account holder engagement and back-office efficiency for community financial institutions (CFIs), today announced the appointment of Tom Shen, Santo Cannone and Laurent Desmangles to its Board of Directors.

Key Points: 
  • Tyfone , the preeminent force in digital transformation, account holder engagement and back-office efficiency for community financial institutions (CFIs), today announced the appointment of Tom Shen, Santo Cannone and Laurent Desmangles to its Board of Directors.
  • Following our recent investment from Demopolis, we have tapped three of the most renowned industry experts to serve on the Board.
  • He currently serves as board chair at Tampa Bay Wave and board member at United Solutions and Simply Reliable.
  • Prabhakar Tadepalli, co-founder, COO and former board member of Tyfone, said, “I am excited to have Tom, Santo, and L.D.

New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)

Retrieved on: 
Wednesday, November 29, 2023

ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.

Key Points: 
  • ADSTILADRIN is the first and only intravesical gene therapy approved by the U.S. Food and Drug Administration (FDA) in this patient population.
  • Patients without evidence of HG recurrence were allowed to continue ADSTILADRIN treatment every three months as part of an ongoing follow-up analysis.
  • Among patients who continued treatment after the 12-month Phase 3 period, 25.5% (14/55 patients) remained HG recurrence-free at 36 months following the start of treatment.
  • At 36 months, the KM-estimated cystectomy-free survival (95% CI) was 53.8% (43.3%, 63.1%), and the three-year overall survival was 90.4% (82.3%, 94.9%).

AWS Announces Four New Capabilities for AWS Supply Chain

Retrieved on: 
Tuesday, November 28, 2023

The existing Demand Planning capability of AWS Supply Chain applies Amazon’s deep supply chain and ML expertise to increase the speed and accuracy of demand forecasts.

Key Points: 
  • The existing Demand Planning capability of AWS Supply Chain applies Amazon’s deep supply chain and ML expertise to increase the speed and accuracy of demand forecasts.
  • AWS Supply Chain chat and messaging capabilities make collaboration even easier across the entire supply chain.
  • Amazon Q in AWS Supply Chain is a generative AI assistant powered by Amazon Bedrock that provides a natural language interface in the AWS Supply Chain application so that customers can query data within the AWS Supply Chain Data Lake, and receive intelligent answers to “what?” and “why?” and “what if?” questions.
  • We are also excited about the next phase of AWS Supply Chain, including advanced supply planning, enriched partner collaboration, and the integration of generative AI, to further improve supply chain performance.”

CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023

Retrieved on: 
Tuesday, November 14, 2023

BOND-003 ( NCT04452591 ) is a single-arm, open-label, Phase 3 clinical trial evaluating cretostimogene grenadenorepvec as monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

Key Points: 
  • BOND-003 ( NCT04452591 ) is a single-arm, open-label, Phase 3 clinical trial evaluating cretostimogene grenadenorepvec as monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
  • The study enrolled 116 patients with BCG-unresponsive NMIBC across North America and the Asia-Pacific region.
  • The primary endpoint of the study is complete response (CR) at any time, with duration of response measured as a secondary endpoint.
  • Details of the oral presentation are as follows:
    Presenter: Mark D. Tyson, M.D., Urologic Oncologist at Mayo Clinic, Scottsdale, AZ